Etiology and outcomes: Thrombotic microangiopathies in pregnancy

A State of the Art lecture titled Etiology and Outcomes of Thrombotic Microangiopathies in Pregnancy was presented at the International Society on Thrombosis and Haemostasis Congress in 2022. First, it is important to understand changes in laboratory parameters in normal pregnancy, including complement levels, specifically the increase in C3, C4, C3a, and C4a throughout pregnancy. Complement is critical in normal pregnancy for implantation and for placental development. Complement-mediated hemolytic uremic syndrome (CMHUS) and thrombotic thrombocytopenic purpura (TTP) can present anytime from the first trimester to the postpartum period. In comparison, Thrombotic microangiopathies specific to pregnancy, such as preeclampsia (PET) or hemolysis, elevated liver enzymes, and low platelets (HELLP), present from the second trimester. C5b-9 deposition (following terminal complement pathway activation) is demonstrated in CM-HUS cases, and in HELLP and few PET cases. PET can also be confirmed and related to severity using soluble fms-like tyrosine kinase-1/placental growth factor ratios. Diagnosis of CM-HUS and TTP in pregnancy can be further complicated by clinical overlap at presentation with PET or occasionally HELLP. Management is aided by ADAMTS-13 analysis to confirm or exclude TTP. Treatment of CM-HUS, in conjunction with supportive care, is complement inhibitor therapy (eculizumab or ravulizumab). Acute TTP requires standard therapy, but caplacizumab should be avoided. Confirmation of congenital or immune subtypes informs care in subsequent pregnancies. Finally, we summarize relevant new data on this topic presented during the 2022 International Society on Thrombosis and Haemostasis Congress.

Automated summary

A State of the Art lecture on the etiology and outcomes of thrombotic microangiopathies (TMAs) in pregnancy was presented at the 2022 International Society on Thrombosis and Haemostasis Congress. The lecture highlighted the importance of understanding changes in laboratory parameters during normal pregnancy and discussed specific TMAs associated with pregnancy, such as preeclampsia (PET) and hemolysis, elevated liver enzymes, and low platelets (HELLP). The presentation also emphasized the complications in diagnosing TMAs in pregnancy and the management strategies for each subtype.